MCID: PNC041
MIFTS: 64

Pancreatic Ductal Adenocarcinoma malady

Categories: Endocrine diseases, Cancer diseases

Aliases & Classifications for Pancreatic Ductal Adenocarcinoma

Aliases & Descriptions for Pancreatic Ductal Adenocarcinoma:

Name: Pancreatic Ductal Adenocarcinoma 38 12 14 69
Ductal Adenocarcinoma of the Pancreas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3498
NCIt 47 C9120
UMLS 69 C1335302

Summaries for Pancreatic Ductal Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that derives from pancreatic duct cells.

MalaCards based summary : Pancreatic Ductal Adenocarcinoma, also known as ductal adenocarcinoma of the pancreas, is related to pancreatitis and adenocarcinoma, and has symptoms including abdominal pain, icterus and pruritus. An important gene associated with Pancreatic Ductal Adenocarcinoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and HIV Life Cycle. The drugs Gemcitabine and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and lymph node, and related phenotypes are Decreased viability and behavior/neurological

Related Diseases for Pancreatic Ductal Adenocarcinoma

Diseases related to Pancreatic Ductal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 181)
id Related Disease Score Top Affiliating Genes
1 pancreatitis 11.2
2 adenocarcinoma 11.2
3 mitochondrial neurogastrointestinal encephalopathy disease 10.4 KRAS SMAD4 TP53
4 pineal region mature teratoma 10.4 EGFR ERBB2
5 exudative glomerulonephritis 10.4 EGFR KRAS TP53
6 clear cell adenofibroma 10.4 CDKN2A TP53
7 oro-mandibular-limb hypogenesis syndrome 10.4 CDKN2A ERBB2 TP53
8 linitis plastica 10.4 CDH1 TP53
9 acquired hemangioma 10.3 CDKN2A ERBB2 TP53
10 intermediate malignant teratoma 10.3 CDKN2A EGFR KRAS
11 familial hypopituitarism 10.3 CDH1 SMAD4 TP53
12 chronic monocytic leukemia 10.3 CDKN2A EGFR TP53
13 urethral villous adenoma 10.3 CDKN2A EGFR PROM1
14 thymus squamous cell carcinoma 10.3 CDKN2A EGFR TP53
15 secondary hyperparathyroidism of renal origin 10.3 CDKN2A EGFR TP53
16 breast ductal carcinoma 10.3 CTNNB1 KRAS TP53
17 endometrial squamous cell carcinoma 10.3 AKT1 CDKN2A TP53
18 wolffian adnexal neoplasm 10.3 EGFR TP53
19 basaloid squamous cell carcinoma 10.3 CDH1 EGFR ERBB2
20 skeletal tuberculosis 10.3 CDKN2A ERBB2
21 adult syndrome 10.3 CTNNB1 KRAS TP53
22 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
23 immunodeficiency due to a late component of complement deficiency 10.3 EGFR ERBB2 TP53
24 his bundle tachycardia 10.3 EGFR ERBB2 TP53
25 combined t cell and b cell immunodeficiency 10.3 CDH1 EGFR ERBB2
26 tamoxifen-related endometrial lesion 10.3 CDKN2A ERBB2 KRAS TP53
27 gastric cancer, somatic 10.3 CDH1 ERBB2 KRAS
28 pityriasis rosea 10.3 CDKN2A EGFR TP53
29 retinal disease 10.3 CDH1 EGFR ERBB2
30 submucosal invasive colon adenocarcinoma 10.3 CTNNB1 SMAD4 TP53
31 severe pre-eclampsia 10.3 EGFR HRAS KRAS
32 interstitial lung disease 10.3 CDKN2A EGFR TP53
33 malignant skin fibrous histiocytoma 10.3 HRAS KRAS
34 bile duct disease 10.3 EGFR HRAS KRAS
35 multicentric papillary thyroid carcinoma 10.3 CTNNB1 EGFR TP53
36 spondylarthropathy 10.3 CDKN2A HRAS TP53
37 uterine corpus endometrial stromal sarcoma 10.3 HRAS KRAS TP53
38 pancreatic cancer 10.3
39 kidney clear cell sarcoma 10.3 EGFR HRAS KRAS
40 vaginal endometrial stromal sarcoma 10.3 AKT1 CDKN2A MSLN
41 bilateral hypoactive labyrinth 10.3 HRAS KRAS SMAD4
42 cervical lymphoepithelioma-like carcinoma 10.3 EGFR ERBB2 MUC1
43 fallopian tube adenocarcinoma 10.3 CDKN2A ERBB2 TP53
44 plasmacytoma 10.3 HRAS KRAS TP53
45 gallbladder pleomorphic giant cell adenocarcinoma 10.3 CDKN2A HRAS TP53
46 adult epithelioid sarcoma 10.3 CDKN2A HRAS TP53
47 striated muscle rhabdoid tumor 10.3 CDKN2A HRAS KRAS
48 reactive arthritis 10.3 CTNNB1 EGFR ERBB2 TP53
49 immunodeficiency due to a classical component pathway complement deficiency 10.3 CDKN2A EGFR MUC1
50 dysembryoplastic neuroepithelial tumor 10.3 CDH1 EGFR ERBB2 TP53

Graphical network of the top 20 diseases related to Pancreatic Ductal Adenocarcinoma:



Diseases related to Pancreatic Ductal Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Ductal Adenocarcinoma

UMLS symptoms related to Pancreatic Ductal Adenocarcinoma:


abdominal pain, icterus, pruritus

GenomeRNAi Phenotypes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.88 KRAS MUC1 EGFR HRAS
2 Decreased viability GR00106-A-0 9.88 KRAS
3 Decreased viability GR00221-A-1 9.88 CDH1 CDKN2A EGFR HRAS KRAS AKT1
4 Decreased viability GR00221-A-2 9.88 HRAS KRAS AKT1
5 Decreased viability GR00221-A-3 9.88 CDKN2A HRAS AKT1
6 Decreased viability GR00221-A-4 9.88 CDKN2A EGFR AKT1
7 Decreased viability GR00301-A 9.88 KRAS CDH1
8 Decreased viability GR00381-A-1 9.88 KRAS
9 Decreased cell migration GR00055-A-1 9.63 AKT1 CTNNB1 EGFR HRAS KRAS MUC1
10 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 CTNNB1 EGFR ERBB2 HRAS MUC1

MGI Mouse Phenotypes related to Pancreatic Ductal Adenocarcinoma:

44 (show all 23)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.42 AKT1 CDKN2A CTNNB1 ERBB2 GLI1 HRAS
2 cellular MP:0005384 10.41 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
3 growth/size/body region MP:0005378 10.4 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
4 homeostasis/metabolism MP:0005376 10.39 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
5 cardiovascular system MP:0005385 10.38 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
6 endocrine/exocrine gland MP:0005379 10.38 TP53 AKT1 CDH1 CDKN2A CTNNB1 EGFR
7 embryo MP:0005380 10.32 GLI1 KRAS PTF1A SMAD4 TP53 AKT1
8 mortality/aging MP:0010768 10.31 SMAD4 TP53 AKT1 CDH1 CDKN2A CTNNB1
9 digestive/alimentary MP:0005381 10.28 CDH1 CDKN2A CTNNB1 EGFR ERBB2 GLI1
10 neoplasm MP:0002006 10.27 PTF1A SMAD4 TP53 AKT1 CDH1 CDKN2A
11 nervous system MP:0003631 10.25 AKT1 CDKN2A CTNNB1 EGFR ERBB2 GLI1
12 craniofacial MP:0005382 10.24 CTNNB1 EGFR ERBB2 GLI1 HRAS KRAS
13 integument MP:0010771 10.24 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
14 limbs/digits/tail MP:0005371 10.18 ERBB2 GLI1 KRAS PTF1A SLC29A1 SMAD4
15 normal MP:0002873 10.18 AKT1 CDH1 CTNNB1 EGFR ERBB2 GLI1
16 no phenotypic analysis MP:0003012 10.14 CDH1 CDKN2A CTNNB1 EGFR GLI1 HRAS
17 liver/biliary system MP:0005370 10.11 AKT1 CDKN2A CTNNB1 EGFR KRAS PTF1A
18 muscle MP:0005369 10.08 AKT1 CDKN2A CTNNB1 EGFR ERBB2 KRAS
19 reproductive system MP:0005389 9.9 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
20 pigmentation MP:0001186 9.8 CDKN2A CTNNB1 EGFR KRAS PROM1 TP53
21 renal/urinary system MP:0005367 9.8 CTNNB1 EGFR GLI1 HRAS KRAS SMAD4
22 respiratory system MP:0005388 9.65 AKT1 CDKN2A CTNNB1 EGFR ERBB2 GLI1
23 skeleton MP:0005390 9.36 ERBB2 HRAS KRAS PTF1A SLC29A1 SMAD4

Drugs & Therapeutics for Pancreatic Ductal Adenocarcinoma

Drugs for Pancreatic Ductal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 1,Phase 2,Early Phase 1 95058-81-4 60750
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2,Early Phase 1 33069-62-4 36314
3
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Pancrelipase Approved Phase 3,Phase 1,Phase 2,Early Phase 1 53608-75-6
6
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
7
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
8
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
9
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741 24759
10
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
12
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
13 Anti-Infective Agents Phase 3,Phase 1,Phase 2,Early Phase 1
14 Antimetabolites Phase 3,Phase 1,Phase 2,Early Phase 1
15 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2,Early Phase 1
16 Antiviral Agents Phase 3,Phase 1,Phase 2,Early Phase 1
17 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Early Phase 1
18 acivicin Phase 3,Phase 2
19 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2,Early Phase 1
20 Antimitotic Agents Phase 3,Phase 1,Phase 2,Early Phase 1
21 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2,Early Phase 1
22 Protective Agents Phase 3,Phase 2,Phase 1
23
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
24 pancreatin Phase 3,Phase 1,Phase 2,Early Phase 1
25 Antidotes Phase 3,Phase 2
26 Micronutrients Phase 3,Phase 2,Phase 1
27 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
28 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
29 Trace Elements Phase 3,Phase 2,Phase 1
30 Vitamin B Complex Phase 3,Phase 2,Phase 1
31 Vitamins Phase 3,Phase 2,Phase 1
32 Protein Kinase Inhibitors Phase 3,Phase 1,Phase 2
33 Liver Extracts Phase 3,Phase 1
34 Adjuvants, Immunologic Phase 3,Phase 1
35 Viscosupplements Phase 3
36 Hematinics Phase 3
37 Folate Nutraceutical Phase 3,Phase 2,Phase 1
38 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
39
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
40
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
41
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
42
Propofol Approved, Investigational, Vet_approved Phase 2,Phase 1 2078-54-8 4943
43
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
44
nivolumab Approved Phase 2,Phase 1 946414-94-4
45
Coal tar Approved Phase 1, Phase 2 8007-45-2
46
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
47
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
48
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
49
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 446556 60843
50
Olaparib Approved Phase 2 763113-22-0 23725625

Interventional clinical trials:

(show top 50) (show all 160)
id Name Status NCT ID Phase
1 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Not yet recruiting NCT02570529 Phase 4
2 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. Completed NCT00471146 Phase 3
3 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
4 A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenoca Recruiting NCT02715804 Phase 3
5 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Recruiting NCT02993731 Phase 3
6 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3
7 Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma Active, not recruiting NCT01526135 Phase 3
8 Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Terminated NCT02101021 Phase 3
9 Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) Unknown status NCT01893801 Phase 1, Phase 2
10 Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma Unknown status NCT01021800 Phase 2
11 Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial Unknown status NCT02440958 Phase 2
12 Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer Unknown status NCT02135822 Phase 2
13 Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer Unknown status NCT00226746 Phase 2
14 Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer Unknown status NCT01394120 Phase 2
15 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Completed NCT01580397 Phase 2
16 A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation Completed NCT02042378 Phase 2
17 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Completed NCT00585078 Phase 2
18 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Completed NCT01658943 Phase 2
19 Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) Completed NCT01808638 Phase 1, Phase 2
20 A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer Completed NCT00902291 Phase 2
21 A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 Completed NCT01608711 Phase 2
22 QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Completed NCT01040000 Phase 1, Phase 2
23 A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Recruiting NCT02981342 Phase 2
24 Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02426281 Phase 2
25 Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02754726 Phase 2
26 PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma Recruiting NCT02487277 Phase 2
27 A Phase II Study of Neoadjuvant FOLFIRINOX Recruiting NCT02178709 Phase 2
28 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Recruiting NCT02810418 Phase 1, Phase 2
29 A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection Recruiting NCT03038477 Phase 2
30 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Recruiting NCT02723331 Phase 2
31 Study of NAC of GA Therapy for Patients With BRPC Recruiting NCT02926183 Phase 2
32 Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Recruiting NCT02125136 Phase 2
33 Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer Recruiting NCT02047513 Phase 2
34 Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Recruiting NCT02562898 Phase 1, Phase 2
35 HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma Recruiting NCT02850874 Phase 2
36 Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer Recruiting NCT02806687 Phase 2
37 Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma Recruiting NCT02743975 Phase 1, Phase 2
38 A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207) Recruiting NCT03085914 Phase 1, Phase 2
39 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2
40 Olaparib for BRCAness Phenotype in Pancreatic Cancer Recruiting NCT02677038 Phase 2
41 Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer Recruiting NCT02529579 Phase 1, Phase 2
42 Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer Recruiting NCT02653313 Phase 1, Phase 2
43 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
44 Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE) Recruiting NCT02576431 Phase 2
45 Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Active, not recruiting NCT02558894 Phase 2
46 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Active, not recruiting NCT02583477 Phase 1, Phase 2
47 Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Active, not recruiting NCT02289898 Phase 2
48 Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients Active, not recruiting NCT02732938 Phase 2
49 Study of Tremelimumab in Patients With Advanced Solid Tumors Active, not recruiting NCT02527434 Phase 2
50 Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla Active, not recruiting NCT02626520 Phase 2

Search NIH Clinical Center for Pancreatic Ductal Adenocarcinoma

Genetic Tests for Pancreatic Ductal Adenocarcinoma

Anatomical Context for Pancreatic Ductal Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Ductal Adenocarcinoma:

39
Pancreas, Lymph Node, Liver, T Cells, Neutrophil, Breast, Adipocyte
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Ductal Adenocarcinoma:
id Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Ducts Affected by disease

Publications for Pancreatic Ductal Adenocarcinoma

Articles related to Pancreatic Ductal Adenocarcinoma:

(show top 50) (show all 874)
id Title Authors Year
1
Adipose Triglyceride Lipase (ATGL) Expression Is Associated with Adiposity and Tumor Stromal Proliferation in Patients with Pancreatic Ductal Adenocarcinoma. ( 28179319 )
2017
2
Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma. ( 27814273 )
2017
3
Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. ( 28062705 )
2017
4
Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway. ( 28315433 )
2017
5
DPC4 gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics. ( 28339284 )
2017
6
Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. ( 28092365 )
2017
7
Analysis of distinct long noncoding RNA transcriptional fingerprints in pancreatic ductal adenocarcinoma. ( 28220683 )
2017
8
Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma. ( 28060763 )
2017
9
KRAS Mutations With No GNAS Mutations in an Intraductal Papillary Mucinous Neoplasm: Are There Common Pathways With Pancreatic Ductal Adenocarcinoma? Lessons From an Extended IPMN, Covering the Entire Pancreas. ( 27977634 )
2017
10
DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. ( 27959420 )
2017
11
Invited Commentary on "Tumor-Vessel Relationships in Pancreatic Ductal Adenocarcinoma at Multidetector CT," with Response from Dr Zaky and Colleagues. ( 28076018 )
2017
12
MiR-181b-5p, ETS1 and c-Met pathway exacerbates the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. ( 28064436 )
2017
13
Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients. ( 28056913 )
2017
14
EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma. ( 27594424 )
2017
15
ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. ( 27862697 )
2017
16
Histologic Tumor Grade and Preoperative Bilary Drainage are the Unique Independent Prognostic Factors of Survival in Pancreatic Ductal Adenocarcinoma Patients After Pancreaticoduodenectomy. ( 28059940 )
2017
17
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. ( 28059968 )
2017
18
Retraction notice to candidate agents for pancreatic ductal adenocarcinoma identified by a sub-pathway based method [GENE 540/2 (2014) 232-7]. ( 27195335 )
2016
19
Circular RNA Expression Profile of Pancreatic Ductal Adenocarcinoma Revealed by Microarray. ( 27997903 )
2016
20
Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma. ( 27665173 )
2016
21
Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. ( 27628540 )
2016
22
dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study. ( 26962792 )
2016
23
TH-EF-BRA-04: Individually Optimized Contrast-Enhanced 4D-CT for Radiotherapy Simulation in Pancreatic Ductal Adenocarcinoma. ( 28048183 )
2016
24
In silico analysis of the transportome in human pancreatic ductal adenocarcinoma. ( 27652669 )
2016
25
The Results of Pancreatic Resections and Long-Term Survival for Pancreatic Ductal Adenocarcinoma: A Single-Institution Experience. ( 27130378 )
2016
26
CLIC1 overexpression is associated with poor prognosis in pancreatic ductal adenocarcinomas. ( 27461670 )
2016
27
HDAC2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma. ( 28028031 )
2016
28
Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. ( 27631521 )
2016
29
Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells. ( 26765963 )
2016
30
Overexpression of SOX18 correlates with accelerated cell growth and poor prognosis in human pancreatic ductal adenocarcinoma. ( 27663663 )
2016
31
Procathepsin E is highly abundant but minimally active in pancreatic ductal adenocarcinoma tumors. ( 27149201 )
2016
32
FOXC2 is up-regulated in pancreatic ductal adenocarcinoma and promotes the growth and migration of cancer cells. ( 26733175 )
2016
33
SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells. ( 27145457 )
2016
34
Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas. ( 26887611 )
2016
35
Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma. ( 26474433 )
2016
36
SERPINB5 Promoter Hypomethylation Differentiates Pancreatic Ductal Adenocarcinoma From Pancreatitis. ( 26646275 )
2016
37
High-Level Expression and Prognostic Significance of Matrix Metalloprotease-19 and Matrix Metalloprotease-20 in Human Pancreatic Ductal Adenocarcinoma. ( 26692439 )
2016
38
Assessment of different 3D culture systems to study tumor phenotype and chemosensitivity in pancreatic ductal adenocarcinoma. ( 27177201 )
2016
39
MiR-221 Promotes Capan-2 Pancreatic Ductal Adenocarcinoma Cells Proliferation by Targeting PTEN-Akt. ( 27230035 )
2016
40
Identification of Novel Serum Autoantibodies for Differential Diagnosis of Autoimmune Pancreatitis and Pancreatic Ductal Adenocarcinoma. ( 27623556 )
2016
41
Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. ( 27178104 )
2016
42
Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma: Characterization in a 3D-cell culture model. ( 27182158 )
2016
43
Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions. ( 26646269 )
2016
44
Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. ( 27689616 )
2016
45
ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. ( 28031255 )
2016
46
RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes. ( 26754001 )
2016
47
Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse Model. ( 27639167 )
2016
48
Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells. ( 26644413 )
2016
49
C1qTNF related protein 4 (CTRP4) promotes pancreatic ductal adenocarcinoma cell proliferation and migration via activation of EGFR-PI3K-NF-I_B pathway. ( 27641756 )
2016
50
MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression. ( 27371108 )
2016

Variations for Pancreatic Ductal Adenocarcinoma

Copy number variations for Pancreatic Ductal Adenocarcinoma from CNVD:

7 (show top 50) (show all 315)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14616 1 109662726 110421733 Loss Pancreatic ductal adenocarcinoma
2 14979 1 111694621 112653686 Loss Pancreatic ductal adenocarcinoma
3 15141 1 11296895 11700048 Loss Pancreatic ductal adenocarcinoma
4 15254 1 113902673 114772618 Loss Pancreatic ductal adenocarcinoma
5 21071 1 156591077 157602759 Gain Pancreatic ductal adenocarcinoma
6 22927 1 16990962 17780550 Loss Pancreatic ductal adenocarcinoma
7 23665 1 172632928 173462394 Gain Pancreatic ductal adenocarcinoma
8 23983 1 174098656 174792564 Gain Pancreatic ductal adenocarcinoma
9 24268 1 17780550 18767187 Loss Pancreatic ductal adenocarcinoma
10 25340 1 18767187 19870518 Loss Pancreatic ductal adenocarcinoma
11 25429 1 189012940 189640525 Gain Pancreatic ductal adenocarcinoma
12 25525 1 190940606 191897513 Gain Pancreatic ductal adenocarcinoma
13 25603 1 191897513 192833019 Gain Pancreatic ductal adenocarcinoma
14 25668 1 192833019 193928417 Gain Pancreatic ductal adenocarcinoma
15 25957 1 195125528 196179631 Gain Pancreatic ductal adenocarcinoma
16 26123 1 197274194 198251428 Gain Pancreatic ductal adenocarcinoma
17 26286 1 19870518 21264484 Loss Pancreatic ductal adenocarcinoma
18 27649 1 210637543 211466127 Gain Pancreatic ductal adenocarcinoma
19 29512 1 232834654 234059648 Gain Pancreatic ductal adenocarcinoma
20 29988 1 23881482 24596143 Loss Pancreatic ductal adenocarcinoma
21 30783 1 24596143 24901021 Loss Pancreatic ductal adenocarcinoma
22 31049 1 24901021 26202341 Loss Pancreatic ductal adenocarcinoma
23 31229 1 26202341 27453508 Loss Pancreatic ductal adenocarcinoma
24 31475 1 27702974 28279739 Loss Pancreatic ductal adenocarcinoma
25 31649 1 29154418 29949616 Loss Pancreatic ductal adenocarcinoma
26 31710 1 29949616 31202941 Loss Pancreatic ductal adenocarcinoma
27 31822 1 31202941 32179980 Loss Pancreatic ductal adenocarcinoma
28 32104 1 33581730 34569385 Loss Pancreatic ductal adenocarcinoma
29 32211 1 34569385 35804738 Loss Pancreatic ductal adenocarcinoma
30 32498 1 36953732 37599763 Loss Pancreatic ductal adenocarcinoma
31 32649 1 38143717 38830556 Loss Pancreatic ductal adenocarcinoma
32 32759 1 3913633 5229374 Loss Pancreatic ductal adenocarcinoma
33 33297 1 44268667 45000776 Loss Pancreatic ductal adenocarcinoma
34 33745 1 47532872 48556325 Loss Pancreatic ductal adenocarcinoma
35 34094 1 5229374 6509870 Loss Pancreatic ductal adenocarcinoma
36 34199 1 53371440 53750907 Loss Pancreatic ductal adenocarcinoma
37 34230 1 53750907 54788971 Loss Pancreatic ductal adenocarcinoma
38 36948 1 8379388 9142502 Loss Pancreatic ductal adenocarcinoma
39 37455 1 9142502 9661749 Loss Pancreatic ductal adenocarcinoma
40 38508 10 103075332 103271952 Gain Pancreatic ductal adenocarcinoma
41 41307 10 15917593 17007248 Gain Pancreatic ductal adenocarcinoma
42 41728 10 22854210 23744923 Gain Pancreatic ductal adenocarcinoma
43 44446 10 57203760 58367659 Gain Pancreatic ductal adenocarcinoma
44 44911 10 64846281 66342495 Gain Pancreatic ductal adenocarcinoma
45 45553 10 72143312 73316160 Loss Pancreatic ductal adenocarcinoma
46 45655 10 73316160 74391172 Gain Pancreatic ductal adenocarcinoma
47 45775 10 74391172 75333936 Gain Pancreatic ductal adenocarcinoma
48 45937 10 75333936 76299818 Gain Pancreatic ductal adenocarcinoma
49 46231 10 79273961 80171344 Loss Pancreatic ductal adenocarcinoma
50 46288 10 80171344 81279277 Loss Pancreatic ductal adenocarcinoma

Expression for Pancreatic Ductal Adenocarcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Pancreatic Ductal Adenocarcinoma patients vs. healthy controls: 35 (show top 50) (show all 375)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SYCN syncollin Pancreas - 8.04 0.000
2 GP2 glycoprotein 2 (zymogen granule membrane) Pancreas - 7.99 0.000
3 ALB albumin Pancreas - 7.95 0.000
4 SERPINI2 serpin peptidase inhibitor, clade I (pancpin), member 2 Pancreas - 7.95 0.000
5 CELA2B chymotrypsin-like elastase family, member 2B Pancreas - 7.74 0.000
6 PNLIPRP1 pancreatic lipase-related protein 1 Pancreas - 7.66 0.000
7 PDIA2 protein disulfide isomerase family A, member 2 Pancreas - 7.53 0.000
8 SPX spexin hormone Pancreas - 7.53 0.000
9 CTRL chymotrypsin-like Pancreas - 7.52 0.000
10 COL10A1 collagen, type X, alpha 1 Pancreas + 7.52 0.000
11 CELP carboxyl ester lipase pseudogene Pancreas - 7.50 0.000
12 COL5A1 collagen, type V, alpha 1 Pancreas + 7.46 0.000
13 SULF1 sulfatase 1 Pancreas + 7.38 0.000
14 CUZD1 CUB and zona pellucida-like domains 1 Pancreas - 7.29 0.000
15 POSTN periostin, osteoblast specific factor Pancreas + 7.24 0.000
16 COL1A1 collagen, type I, alpha 1 Pancreas + 7.17 0.000
17 AQP8 aquaporin 8 Pancreas - 7.14 0.000
18 CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 Pancreas + 7.10 0.000
19 COL11A1 collagen, type XI, alpha 1 Pancreas + 7.00 0.000
20 CLPS colipase, pancreatic Pancreas - 6.99 0.000
21 INHBA inhibin, beta A Pancreas + 6.95 0.000
22 CPA2 carboxypeptidase A2 (pancreatic) Pancreas - 6.88 0.000
23 CTRC chymotrypsin C (caldecrin) Pancreas - 6.87 0.000
24 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) Pancreas + 6.86 0.000
25 PLA2G1B phospholipase A2, group IB (pancreas) Pancreas - 6.79 0.001
26 COL3A1 collagen, type III, alpha 1 Pancreas + 6.78 0.000
27 SFRP4 secreted frizzled-related protein 4 Pancreas + 6.76 0.000
28 CELA3A chymotrypsin-like elastase family, member 3A Pancreas - 6.76 0.001
29 GNMT glycine N-methyltransferase Pancreas - 6.74 0.000
30 COL1A2 collagen, type I, alpha 2 Pancreas + 6.72 0.000
31 REG1P regenerating islet-derived 1 pseudogene Pancreas - 6.72 0.000
32 S100P S100 calcium binding protein P Pancreas + 6.67 0.000
33 CELA3B chymotrypsin-like elastase family, member 3B Pancreas - 6.66 0.001
34 CEL carboxyl ester lipase Pancreas - 6.63 0.001
35 CTHRC1 collagen triple helix repeat containing 1 Pancreas + 6.60 0.000
36 CPA1 carboxypeptidase A1 (pancreatic) Pancreas - 6.56 0.001
37 VCAN versican Pancreas + 6.51 0.000
38 TMEM52 transmembrane protein 52 Pancreas - 6.40 0.000
39 REG1B regenerating islet-derived 1 beta Pancreas - 6.35 0.002
40 CTSE cathepsin E Pancreas + 6.30 0.000
41 GLS2 glutaminase 2 (liver, mitochondrial) Pancreas - 6.28 0.000
42 KLK1 kallikrein 1 Pancreas - 6.26 0.000
43 GJB2 gap junction protein, beta 2, 26kDa Pancreas + 6.24 0.000
44 REG3G regenerating islet-derived 3 gamma Pancreas - 6.17 0.000
45 PLAU plasminogen activator, urokinase Pancreas + 6.15 0.000
46 COL5A2 collagen, type V, alpha 2 Pancreas + 6.13 0.000
47 SLC39A5 solute carrier family 39 (zinc transporter), member 5 Pancreas - 6.09 0.000
48 ERP27 endoplasmic reticulum protein 27 Pancreas - 6.07 0.000
49 SEMA3C sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C Pancreas + 6.00 0.000
50 PNLIP pancreatic lipase Pancreas - 5.94 0.004
Search GEO for disease gene expression data for Pancreatic Ductal Adenocarcinoma.

Pathways for Pancreatic Ductal Adenocarcinoma

Pathways related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 94)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
2
Show member pathways
13.81 AKT1 CDH1 CTNNB1 EGFR ERBB2 HRAS
3
Show member pathways
13.58 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
4
Show member pathways
13.39 AKT1 CDH1 CTNNB1 EGFR ERBB2 HRAS
5
Show member pathways
13.36 AKT1 CDH1 CTNNB1 EGFR ERBB2 HRAS
6
Show member pathways
13.08 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
7
Show member pathways
13.07 AKT1 CDH1 CTNNB1 HRAS KRAS TP53
8
Show member pathways
12.98 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
9
Show member pathways
12.98 AKT1 CDKN2A EGFR GLI1 HRAS KRAS
10
Show member pathways
12.95 AKT1 CTNNB1 HRAS KRAS TP53
11
Show member pathways
12.87 AKT1 CDH1 CTNNB1 ERBB2 HRAS KRAS
12
Show member pathways
12.82 AKT1 CDH1 CTNNB1 EGFR HRAS KRAS
13
Show member pathways
12.81 AKT1 EGFR ERBB2 HRAS KRAS TP53
14 12.79 AKT1 EGFR HRAS KRAS TP53
15
Show member pathways
12.74 AKT1 EGFR HRAS KRAS TP53
16 12.68 AKT1 EGFR HRAS KRAS TP53
17
Show member pathways
12.66 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
18 12.6 CDKN2A EGFR ERBB2 HRAS KRAS TP53
19
Show member pathways
12.59 AKT1 EGFR ERBB2 HRAS KRAS TP53
20
Show member pathways
12.52 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
21
Show member pathways
12.5 AKT1 CTNNB1 EGFR HRAS KRAS
22 12.5 AKT1 CDKN2A CTNNB1 HRAS KRAS SMAD4
23
Show member pathways
12.45 CTNNB1 GLI1 HRAS KRAS TP53
24
Show member pathways
12.45 AKT1 CDH1 CTNNB1 EGFR ERBB2 HRAS
25 12.43 CDH1 CDKN2A SMAD4 TP53
26
Show member pathways
12.43 AKT1 EGFR HRAS KRAS
27
Show member pathways
12.39 AKT1 EGFR ERBB2 HRAS
28 12.39 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
29
Show member pathways
12.38 AKT1 EGFR ERBB2 HRAS KRAS
30
Show member pathways
12.38 AKT1 EGFR ERBB2 HRAS KRAS TP53
31 12.37 CDKN2A HRAS KRAS TP53
32
Show member pathways
12.33 AKT1 HRAS KRAS TP53
33
Show member pathways
12.33 AKT1 CDH1 CTNNB1 EGFR ERBB2 HRAS
34 12.32 CTNNB1 GLI1 PROM1 SMAD4
35
Show member pathways
12.31 AKT1 EGFR HRAS KRAS
36 12.29 AKT1 CDH1 CTNNB1 EGFR KRAS SMAD4
37 12.29 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
38 12.28 AKT1 EGFR ERBB2 HRAS KRAS
39
Show member pathways
12.28 AKT1 EGFR ERBB2 KRAS TP53
40
Show member pathways
12.26 AKT1 HRAS KRAS TP53
41
Show member pathways
12.24 AKT1 EGFR ERBB2 HRAS KRAS
42
Show member pathways
12.22 AKT1 HRAS KRAS TP53
43
Show member pathways
12.22 AKT1 HRAS KRAS TP53
44
Show member pathways
12.21 AKT1 CTNNB1 EGFR ERBB2 HRAS
45 12.21 AKT1 CDH1 CTNNB1 EGFR KRAS SMAD4
46 12.19 AKT1 HRAS KRAS TP53
47 12.17 AKT1 CTNNB1 HRAS KRAS SMAD4
48 12.17 AKT1 CDH1 HRAS KRAS SMAD4
49 12.16 AKT1 CDKN2A KRAS TP53
50
Show member pathways
12.16 AKT1 EGFR HRAS KRAS SMAD4

GO Terms for Pancreatic Ductal Adenocarcinoma

Cellular components related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 basolateral plasma membrane GO:0016323 9.46 CTNNB1 EGFR ERBB2 SLC29A1
2 catenin complex GO:0016342 9.32 CDH1 CTNNB1
3 flotillin complex GO:0016600 9.26 CDH1 CTNNB1
4 vesicle GO:0031982 9.26 AKT1 MUC1 MUC4 PROM1
5 apical plasma membrane GO:0016324 9.02 EGFR ERBB2 MUC1 PROM1 SLC29A1

Biological processes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 27)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.98 CTNNB1 ERBB2 HRAS KRAS TP53
2 positive regulation of cell proliferation GO:0008284 9.97 CTNNB1 EGFR GLI1 HRAS KRAS SLC35F6
3 positive regulation of apoptotic process GO:0043065 9.96 AKT1 CDKN2A CTNNB1 NUPR1 TP53
4 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.91 AKT1 CDKN2A CTNNB1 EGFR GLI1 HRAS
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.83 HRAS KRAS MUC1 MUC4
6 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.81 AKT1 EGFR ERBB2
7 positive regulation of epithelial cell proliferation GO:0050679 9.79 EGFR ERBB2 HRAS
8 phosphatidylinositol-mediated signaling GO:0048015 9.78 AKT1 EGFR ERBB2 TP53
9 epidermal growth factor receptor signaling pathway GO:0007173 9.77 EGFR HRAS KRAS
10 positive regulation of protein phosphorylation GO:0001934 9.77 AKT1 EGFR ERBB2 HRAS KRAS
11 Ras protein signal transduction GO:0007265 9.73 CDKN2A HRAS KRAS TP53
12 cellular response to epidermal growth factor stimulus GO:0071364 9.72 AKT1 EGFR ERBB2
13 positive regulation of DNA replication GO:0045740 9.71 EGFR GLI1 HRAS
14 positive regulation of MAP kinase activity GO:0043406 9.71 EGFR ERBB2 HRAS KRAS
15 retina morphogenesis in camera-type eye GO:0060042 9.63 PROM1 PTF1A
16 pancreas development GO:0031016 9.63 CTNNB1 MSLN PTF1A
17 response to isolation stress GO:0035900 9.62 HRAS KRAS
18 cellular response to growth factor stimulus GO:0071363 9.62 AKT1 CTNNB1 EGFR ERBB2
19 positive regulation of cellular senescence GO:2000774 9.61 CDKN2A KRAS
20 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.59 AKT1 EGFR
21 negative regulation of immature T cell proliferation in thymus GO:0033088 9.58 CDKN2A ERBB2
22 cellular response to indole-3-methanol GO:0071681 9.57 CDH1 CTNNB1
23 response to UV-A GO:0070141 9.51 AKT1 EGFR
24 cell proliferation GO:0008283 9.5 AKT1 CTNNB1 EGFR ERBB2 HRAS SMAD4
25 ERBB2 signaling pathway GO:0038128 9.46 EGFR ERBB2 HRAS KRAS
26 positive regulation of transcription, DNA-templated GO:0045893 9.28 AKT1 CDH1 CDKN2A CTNNB1 EGFR GLI1
27 negative regulation of cell proliferation GO:0008285 10.02 CDKN2A CTNNB1 HRAS SMAD4 TP53

Molecular functions related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.77 AKT1 EGFR ERBB2 HRAS KRAS
2 transcription regulatory region DNA binding GO:0044212 9.73 CTNNB1 GLI1 SMAD4 TP53
3 protein kinase binding GO:0019901 9.72 AKT1 CDKN2A CTNNB1 EGFR TP53
4 I-SMAD binding GO:0070411 9.46 CTNNB1 SMAD4
5 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.4 EGFR ERBB2
6 RNA polymerase II transcription factor binding GO:0001085 9.33 CTNNB1 SMAD4 TP53
7 nitric-oxide synthase regulator activity GO:0030235 9.26 AKT1 EGFR
8 protein phosphatase binding GO:0019903 9.26 CTNNB1 EGFR ERBB2 TP53
9 chromatin binding GO:0003682 9.17 CTNNB1 EGFR GLI1 NUPR1 PTF1A SMAD4

Sources for Pancreatic Ductal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....